Related Experiment Video
Updated: Jan 26, 2026
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
Efficacy of ivabradine for heart failure: A protocol for a systematic review of randomized controlled trial
En-Zhong Xue1, Ming-Hui Zhang2, Chun-Li Liu1
1Department of Cardiology.
Insights
This systematic review evaluates ivabradine for heart failure (HF). It synthesizes evidence on ivabradine
Area of Science:
- Cardiology
- Pharmacology
- Evidence-Based Medicine
Background:
- Heart failure (HF) is a significant global health concern.
- Ivabradine has shown potential in treating HF in previous trials.
- A comprehensive systematic review on ivabradine's efficacy and safety in HF is lacking.
Purpose of the Study:
- To systematically evaluate the efficacy and safety of ivabradine for treating patients with heart failure.
- To synthesize current evidence from randomized controlled trials (RCTs) on ivabradine in HF management.
Main Methods:
- Comprehensive literature search of multiple databases (e.g., MEDLINE, EMBASE, Cochrane) up to January 31, 2019.
- Inclusion of all RCTs on ivabradine for HF, with data extraction and risk of bias assessment by two independent researchers.
- Meta-analysis will be performed using fixed- or random-effects models where appropriate.
Main Results:
- Primary outcome: all-cause mortality.
- Secondary outcomes: changes in body weight, urine output, serum sodium levels, and incidence of adverse events.
Conclusions:
- This systematic review will provide updated evidence on the efficacy and safety of ivabradine for heart failure.
- Findings will aid clinicians in making informed treatment decisions for HF patients.
Background:
Previous clinical trials have reported that ivabradine can effectively treat heart failure (HF). However, no systematic review has explored its efficacy and safety for HF. This systematic review will aim to evaluate the efficacy and safety of ivabradine for the treatment of patients with HF.
Methods:
We will search the literature from the following electronic databases from inception to the January 31, 2019: Cochrane Central Register of Controlled Trials, EMBASE, MEDILINE, Web of Science, Cumulative Index to Nursing and Allied Health Literature, Allied and Complementary Medicine Database, Chinese Biomedical Literature Database, China National Knowledge Infrastructure, VIP Information, and Wanfang Data. All randomized controlled trials (RCTs) of ivabradine for HF will be fully considered for inclusion without any restrictions. Additionally, grey literature including clinical trial registries, dissertations, and reference lists of included studies, conference abstracts will also be searched. Two researchers will review these literatures, extract data, and assess risk of bias of included RCTs separately. Data will be pooled by either fixed-effects model or random-effects model, and meta-analysis will be conducted if it is appropriate.
Results:
The primary outcome is all-cause mortality. The secondary outcomes comprise of change in body weight, urine output, change in serum sodium, and all adverse events.
Conclusions:
The results of this study will summary provide up-to-dated evidence for assessing the efficacy and safety of ivabradine for HF.
Ethics And Dissemination:
It is not necessary to acquire ethical approval for this systematic review, because no individual patient data will be used in this study. The results of this systematic review will be published through peer-reviewed journals.
Systematic Review Registration:
PROSPERO CRD42019120814.
Related Concept Videos
01:20Random and Systematic Errors
01:29Heart Failure II: Pathophysiology
01:17Pathophysiology of Heart Failure
01:27Heart Failure I: Introduction
01:22Heart Failure VI: Adjunct Therapies
01:22Heart Failure Drugs: Diuretics